Pfizer shares fell as much as 3.1% after Dow Jones reported that the company expected to ship half of the Covid-19 vaccines it had originally planned for 2020 because of supply-chain problems. “Scaling up the raw material supply chain took longer than expected,” a company spokeswoman told Dow Jones